News
OPGN
3.060
+0.07%
0.002
Weekly Report: what happened at OPGN last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at OPGN last week (0708-0712)?
Weekly Report · 07/15 09:52
OPGN Stock Earnings: OpGen Reported Results for Q1 2024
OpGen just reported results for the first quarter of 2024. OpGen reported earnings per share of 20.7 cents. The company reported revenue of $168,149. Opgen is a biotechnology company with a focus on cancer treatment and stem cell research in the U.S.
Investorplace · 07/09 01:52
Weekly Report: what happened at OPGN last week (0701-0705)?
Weekly Report · 07/08 09:52
Weekly Report: what happened at OPGN last week (0624-0628)?
Weekly Report · 07/01 09:52
Weekly Report: what happened at OPGN last week (0617-0621)?
Weekly Report · 06/24 09:55
Weekly Report: what happened at OPGN last week (0610-0614)?
Weekly Report · 06/17 09:52
OPGEN INC - RECEIVED NASDAQ NOTICE THAT CO IS NOT IN COMPLIANCE WITH MINIMUM STOCKHOLDERS' EQUITY REQUIREMENT FOR CONTINUED LISTING ON NASDAQ
Reuters · 06/11 20:26
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Viracta Therapeutics (NASDAQ:VIRX) stock increased by 16.8% to $0.68 during Tuesday's pre-market session. Purple Biotech stock rose by 14.48% and Akanda stock rose 12.54% during the same time period. Losers ProKidney ( NASDAQ:PROK) shares decreased by 12.9% in the same session.
Benzinga · 06/11 12:06
Weekly Report: what happened at OPGN last week (0603-0607)?
Weekly Report · 06/10 09:53
OPGN Stock Earnings: OpGen Meets Revenue for Q4 2023
OpGen reported results for the fourth quarter of 2023. OpGen reported earnings per share of -$17.67. The company reported revenue of $1.07 million. This was the same as the analyst estimate for revenue of  $1.08 million.
Investorplace · 06/05 13:53
Weekly Report: what happened at OPGN last week (0527-0531)?
Weekly Report · 06/03 09:54
Weekly Report: what happened at OPGN last week (0520-0524)?
Weekly Report · 05/27 09:56
OPGEN RECEIVES EXPECTED NASDAQ NOTICE REGARDING DELAYED FORM 10-Q
Reuters · 05/24 20:05
OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q
OpGen, Inc. Is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024. The Nasdaq Hearings Panel will consider delisting the Company’s securities from Nasdaq.
Barchart · 05/24 15:05
Weekly Report: what happened at OPGN last week (0513-0517)?
Weekly Report · 05/20 09:53
OPGEN ANNOUNCED 1-FOR-10 REVERSE STOCK SPLIT
Reuters · 05/16 11:00
OPGEN : REVERSE STOCK SPLIT WILL INCREASE MARKET PRICE PER SHARE OF COMMON STOCK IN ORDER TO REGAIN COMPLIANCE WITH NASDAQ
Reuters · 05/16 11:00
Weekly Report: what happened at OPGN last week (0506-0510)?
Weekly Report · 05/13 09:57
GoodRx Holdings, Inc. (GDRX) Misses Q1 Earnings Estimates
NASDAQ · 05/09 11:20
More
Webull provides a variety of real-time OPGN stock news. You can receive the latest news about Opgen through multiple platforms. This information may help you make smarter investment decisions.
About OPGN
OpGen, Inc. is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company distributes molecular microbiology solutions that help guide clinicians with more information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The Company's product portfolio includes Unyvero Lower Respiratory Tract Panels, Unyvero Urinary Tract Infection Panel, Unyvero System, and Unyvero Resources. The Unyvero LRT panels enable comprehensive detection of the most clinically relevant pathogens and antibiotic resistance markers. The Unyvero Urinary Tract Infection (UTI) panel simultaneously identifies a comprehensive range of pathogens and antibiotic resistance markers associated with urinary tract infections. The Unyvero system uses multiplex PCR technology to simultaneously test for a range of microorganisms and antibiotic resistance markers.